Today: 19 April 2026
Subscribe
Browse Category

NYSE:DDD 9 December 2025 - 9 March 2026

3D Systems Corporation beats Q4 sales guidance, but weak Q1 outlook clouds recovery

3D Systems Corporation beats Q4 sales guidance, but weak Q1 outlook clouds recovery

3D Systems reported fourth-quarter revenue of $106.3 million, up 16% from the prior quarter and above its forecast, but still down 4% from a year earlier. Full-year revenue dropped 12% to $386.9 million, with a net income gain driven by asset sales and cost cuts. Healthcare Solutions rose 25% while Industrial Solutions fell 21%. The company expects a first-quarter revenue decline and continued losses.
9 March 2026
··
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

TuHURA Biosciences plunged 36.9% after announcing a $15.6 million direct offering with warrants, triggering heavy dilution concerns. Phreesia, Euda Health, SLM Corp, Virgin Galactic, and Gogo each fell more than 15%. Major indexes stayed mostly flat, with the Dow up 0.2% and the S&P 500 up 0.1% as traders awaited the Federal Reserve’s policy decision.
9 December 2025
··········

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop